Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Portfolio Pulse from
Relay Therapeutics and Elevar Therapeutics have entered into an exclusive global licensing agreement for the development and commercialization of lirafugratinib, a treatment for FGFR2-driven cholangiocarcinoma and other solid tumors. Elevar Therapeutics gains worldwide rights to the drug.
December 03, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relay Therapeutics has granted Elevar Therapeutics exclusive global rights to develop and commercialize lirafugratinib, potentially expanding its market reach and revenue streams.
The licensing agreement allows Relay Therapeutics to potentially benefit from Elevar's commercialization efforts, expanding the drug's market presence and increasing potential revenue.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80